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AbsTrACT
Objectives evaluation of rituximab and glucocorticoids 
as therapy to induce remission after relapse in anCa- 
associated vasculitis (aaV) in a prospective observational 
cohort of patients enrolled into the induction phase of 
the RiTaZaReM trial.
Methods Patients relapsing with granulomatosis with 
polyangiitis or microscopic polyangiitis were prospectively 
enrolled and received remission- induction therapy with 
rituximab (4×375 mg/m2) and a higher or lower dose 
glucocorticoid regimen, depending on physician choice: 
reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 
10 mg/day by 4 months. Patients in this cohort achieving 
remission were subsequently randomised to receive one 
of two regimens to prevent relapse.
results 188 patients were studied: 95/188 (51%) men, 
median age 59 years (range 19–89), prior disease duration 
5.0 years (range 0.4–34.5). 149/188 (79%) had previously 
received cyclophosphamide and 67/188 (36%) rituximab. 
119/188 (63%) of relapses had at least one major disease 
activity item, and 54/188 (29%) received the higher 
dose glucocorticoid regimen. 171/188 (90%) patients 
achieved remission by 4 months. Only six patients (3.2% 
of the study population) did not achieve disease control 
at month 4. Four patients died in the induction phase due 
to pneumonia (2), cerebrovascular accident (1), and active 
vasculitis (1). 41 severe adverse events occurred in 27 
patients, including 13 severe infections.
Conclusions This large prospective cohort of patients 
with relapsing aaV treated with rituximab in conjunction 
with glucocorticoids demonstrated a high level of efficacy 
for the reinduction of remission in patients with aaV who 
have relapsed, with a similar safety profile to previous 
studies.
InTrOduCTIOn
Granulomatosis with polyangiitis (GPA) and micro-
scopic polyangiitis (MPA) are the major subgroups 
of antineutrophil cytoplasmic antibody (ANCA)- 
associated vasculitis (AAV). These conditions are 
characterised by leucocyte infiltration of blood 
vessel walls, fibrinoid necrosis and vascular damage 
and are usually associated with the presence of 
circulating ANCA.1
Prior to the availability of effective treatment, 
AAV had a mortality of 93% within 2 years, 
primarily due to renal and respiratory failure.2 The 
introduction of glucocorticoids and cyclophospha-
mide, which became established treatment for this 
disease in the 1980s, markedly improved survival, 
inducing remission at 1 year in approximately 80% 
of patients. However, relapsing disease is common 
with over 50% of patients experiencing a relapse 
within 5 years and the majority suffering treatment- 
related toxicity.3–5
B- lymphocytes have been implicated in the 
pathogenesis of AAV. Rituximab is a murine/human 
chimeric monoclonal antibody directed against 
Key messages
What is already known about this subject?
 ► Rituximab is increasingly being used as a 
remission induction agent in ANCA- associated 
vasculitis.
What does this study add?
 ► This large prospective cohort provides further 
efficacy and safety data for the use of rituximab 
in patients specifically with relapsing disease.
How might this impact on clinical practice or 
future developments?
 ► Rituximab in conjunction with glucocorticoids is 
now an established induction strategy in ANCA- 
associated vasculitis.
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Figure 1 Consort diagram.
the CD20 antigen found on the surface of B- lymphocytes and 
results in B cell depletion. Rituximab was shown to be non- 
inferior to cyclophosphamide for induction of remission in AAV 
and superior to cyclophosphamide for the treatment of relapsing 
disease.6 7 Rituximab became a licenced therapy for remission 
induction of AAV in 2011.
Fixed- interval, repeat- dosing of rituximab was shown to be 
superior to azathioprine as a maintenance strategy following 
induction of remission cyclophosphamide in a trial of 117 
patients with predominantly newly diagnosed AAV.8 The optimal 
strategy to maintain remission following induction of remission 
with rituximab, especially for treatment of relapse, is not clear. 
RITAZAREM was an international, randomised, controlled trial 
designed to assess whether rituximab is superior to azathio-
prine for the maintenance of remission following induction of 
remission with rituximab and glucocorticoids in patients with 
relapsing AAV. In this trial, fixed- interval, repeat doses of ritux-
imab were compared with daily azathioprine for maintenance of 
remission.
Since all patients received rituximab for induction of remis-
sion in the RITAZAREM trial, this is the largest reported 
prospective cohort of patients with relapsing AAV to receive 
treatment with rituximab for induction of remission. This first 
report outlines the efficacy and safety of rituximab with either 
higher or lower dose glucocorticoids for induction of remission 
in a large prospective cohort of patients with relapsing AAV.
MeTHOds
The details of the RITAZAREM protocol have been previously 
published.9 In summary, RITAZAREM trial has three phases:
1. An induction phase (months 0–4): eligible patients enrolled 
at time of disease relapse received rituximab (4 weekly doses 
of 375 mg/m2) and glucocorticoids.
2. A maintenance phase (months 4–24): 4 months after en-
rolment, participants who achieved remission (defined as a 
Birmingham Vasculitis Activity Score for Wegener’s gran-
ulomatosis (BVAS/WG) ≤1 and prednisone/prednisolone 
dose ≤10 mg/day) were randomised in 1:1 ratio to receive 
1000 mg rituximab at 4 monthly fixed intervals or daily aza-
thioprine (2 mg/kg/day).
3. A follow- up phase: clinical follow- up after completion of 
therapy with either rituximab or azathioprine (minimum of 
12, maximum of 24 months).
This paper reports on the first, induction phase of the trial, 
prior to randomisation.
Participants
Participants were aged over 15 years and had a diagnosis of GPA 
or MPA according to Chapel Hill Consensus Conference defini-
tions10 and a current or historical positive test for PR3- ANCA 
or MPO- ANCA. All patients had disease relapse defined by one 
major or three minor disease activity items on the BVAS/WG and 
had previously achieved remission following at least 3 months of 
induction therapy, with a combination of glucocorticoids and an 
immunosuppressive agent (cyclophosphamide, rituximab, meth-
otrexate or mycophenolate mofetil).
Key exclusion criteria included the receipt of any biological B 
cell depleting agents within the previous 6 months, alemtuzumab 
or antithymocyte globulin within the previous 12 months, or 
intravenously administered immunoglobulin, plasma exchange copyright.
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Table 1 Baseline demographics
Total
(n=188)
Age, years: median (range) 59 (19–89)
Male, number (%) 95 (51)
Race, number (%)
  White 168 (89.4)
  Asian 13 (6.9)
  Hispanic 3 (1.6)
  Black 1 (0.5)
  Other 3 (1.6)
Disease duration, years: median (range) 5.0 (0.4–34.5)
Prior treatment with cyclophosphamide
  Number of patients (%) 149 (79.3)
  Cumulative dose, grams (g): median (range) 9 (0.15–301)
Prior rituximab therapy
  Number of patients (%) 67 (35.6)
  Cumulative dose, grams (g): median (range) 3910 (1000–16000)
Glucocorticoid induction regimen, number (%)
  1 mg/kg/day starting dose (1A) 54 (28.7)
  0.5 mg/kg/day starting dose (1B) 134 (71.3)
ANCA type, number (%)
  Antiproteinase 3 137 (72.9)
  Antimyeloperoxidase 51 (27.1)
Relapse type on entry into trial, number (%)
  Severe 119 (63.3)
  Non- severe 69 (36.7)
BVAS/WG: median (range) 5 (3–14)
ANCA, antineutrophil cytoplasmic antibody; BVAS/WG, Birmingham Vasculitis 
Activity Score for Wegener's granulomatosis.
or anti- tumour necrosis factor (TNF) treatment within the 
previous 3 months. Patients with other multisystem autoim-
mune diseases, such as eosinophilic granulomatous with poly-
angiitis, systemic lupus erythematosus, antiglomerular basement 
membrane disease or cryoglobulinaemic vasculitis or history of 
malignancy within the past 5 years were also excluded.
Participants were recruited from 29 centres in seven countries.
Interventions and induction therapy
Rituximab
Rituximab 375 mg/m2/week was administered in four doses.
Glucocorticoids
Investigators chose from one of two glucocorticoid regimens 
taking into consideration disease severity and local prescribing 
practices. Schedule 1A had a glucocorticoid starting dose of 
1 mg/kg/day (maximum 60 mg daily) and 1B had a starting dose 
of 0.5 mg/kg/day (maximum 30 mg daily), both tapering to 
10 mg daily by month 4. Deviation from the protocol- specified 
tapering glucocorticoid regimen was defined as a 25% higher or 
lower glucocorticoid dose, averaged over 2 weeks. Patients could 
also receive a maximum cumulative dose of 3000 mg intrave-
nous methylprednisolone, between 14 days prior to enrolment 
and 7 days after enrolment.
Other treatments
Prophylaxis to prevent pneumocystis (carinii) jiroveci infection 
and/or to prevent osteoporosis were recommended according to 
local practice. Plasma exchange could be administered during the 
induction period following local practice. However, rituximab 
was not administered within 48 hours before a plasma exchange 
treatment.
Assessments
Evaluations (including clinical, biochemical and patient- reported 
outcomes) were performed at 0, 1.5, 3 and 4 months.
Power calculation
Enrolment was set to be open until at least 160 patients were 
randomised at their month 4 visits. It was anticipated that 190 
patients would be required in order to randomise 160 patients. 
Details of how the sample size was determined have been previ-
ously published.9
Definitions
Remission was defined as a BVAS/WG of 1 or less with a predni-
sone/prednisolone dose of 10 mg/day or less by 4 months.
Statistical methods
Continuous variables are expressed as medians and IQRs. Cate-
gorical variables are presented as percentages and frequencies. A 
set of univariate logistic regression analyses to predict remission 
at month 4 for candidate factors was performed. Estimates of 
marginal ORs, with 95% CIs and p values are presented. The 
statistical comparisons were not formally powered or prespec-
ified in the protocol so these results must be interpreted with 
caution. Data were analysed using R V.3.6.1.
resulTs
baseline demographics
188 patients were enrolled into the trial. Patient disposition 
throughout the 4- month induction period is shown in the consort 
diagram (figure 1) and baseline demographics in table 1. Ninety- 
five out of 188 (51%) patients were male, with a median age of 
59 years (range 19–89) and prior disease duration of 5.0 years 
(range 0.4–34.5). One hundred and forty- nine (79%) patients 
had previously received cyclophosphamide (median dose 9 g 
(range 0.15–301) and 67/188 (36%) had received rituximab 
(median dose 3910 mg (range 1000–16000)). At enrolment, 
60/188 (32%) patients were on an oral immunosuppressive 
agent: (35/188 (19%) azathioprine; 12/188 (6%) mycopheno-
late mofetil; and 13/188 (7%) methotrexate), each of which 
were stopped as per protocol. One hundred and thirty- seven out 
of 188 (73%) had a history of a positive test for PR3- ANCA and 
51/188 (37%) for MPO- ANCA. One hundred and nineteen out 
of 188 (63%) of relapses had at least one major disease activity 
item, and 54/188 (29%) patients received the higher dose gluco-
corticoid regimen. The median BVAS/WG at enrolment was 5 
(range 3–14). Distribution of baseline disease manifestations 
included: ear, nose and throat: 120/187 (64.2%) patients, renal: 
88 (47.1%) patients and respiratory involvement: 69 (36.9%) 
patients.
The median number of body systems previously affected by 
vasculitis was 5 (range 0–10). Prior organ involvement included 
renal in 127/188 (67.6%) patients, lung in 115/188 (61.2%) 
patients and ear nose and throat in 138/188 (73.4%) patients. 
Hypertension was common, affecting 93/199 (49.5%) patients. 
Twenty- three out of 188 (12.2%) patients had diabetes mellitus 
at enrolment; 29/188 (15.4%) had chronic lung disease and 
20/188 (10.6%) had previously suffered from malignancy.
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Figure 2 Disease response according to baseline BVAS/WG score. Figures represent the number of individuals according to disease status. In 
addition to those displayed on the graph: at month 1.5, two individuals had severe disease, and four were withdrawn/missing. At month 3, one 
individual had severe disease and one limited disease. At month 4, one individual had severe disease, three had limited disease and three had 
persistent disease. Withdrawn/missing includes all participants who did not attend a study visit either due to death, withdrawal from trial or a missed 
visit. BVAS/WG, Birmingham Vasculitis Activity Score for Wegener’s granulomatosis.
Treatment exposure
The median total dose of rituximab in the induction phase was 
2937 mg (range 1552–4320 mg) and cumulative oral glucocor-
ticoid exposure in the 4- month induction phase was 3010 mg 
(2485–7875 mg) in the 1A higher dose induction regimen 
and 1960 mg (1715–3535 mg) in the 1B lower dose induction 
regimen. There was no difference in cumulative glucocorticoid 
exposure between patients that achieved and did not achieve 
remission (median dose 1960 mg in both groups (1A range: 
1715–3010; 1B range: 1715–7875). Twenty- five per cent of 
patients deviated from the specified glucocorticoid tapering 
regimen at some point in the induction phase.
disease response
One hundred and seventy- one out of 188 (90%) patients 
achieved remission at month 4 (figure 2). Of the 17 patients who 
did not achieve remission by month 4, 13 (76%) had PR3- ANCA 
positive disease and 10 (59%) had ear, nose and throat involve-
ment at baseline. Fourteen out of 17 (82%) patients who did not 
achieve remission had severe (at least one major BVAS/WG item) 
disease and 5/17 patients (29%) received the higher glucocorti-
coid dosing regimen. Seven out of 17 (41.2%) non- responders 
had previously received rituximab, median cumulative dose of 
4125 mg (1000–8930), which was comparable with responders 
(60/171 (35.1%), and cumulative dose 3910 mg (1500–16000)). 
At month 4, three patients had ongoing ENT disease activity; 
three had pulmonary manifestations; two had active renal 
disease; and four had other features of active disease (fatigue,2 
pachymeningitis1 and headache1). None of the following base-
line variables were predictive of disease response: age, ANCA 
type at enrolment, glucocorticoid induction regimen, presence 
of ear, nose and throat or renal involvement (online supplemen-
tary table 1), although it is notable non- severe disease was asso-
ciated with an OR of 2.93, 95% CI 0.915 to 13.1 for subsequent 
response. Of the 17 patients who did not progress in the trial, 
only 6/188 (3.2%) had a failure to achieve disease control at 
month 4, four died in the induction phase, two were withdrawn 
by their investigator (diagnosis of a new malignancy and occur-
rence of serious adverse events (SAEs)), three withdrew consent, 
one required additional therapy not permitted in the protocol 
and one failed screening and did not receive induction therapy.
biochemical parameters
Median B cell count fell from 0.12×109/L (12%) (range 0–3.49 
(0%–46%)) at baseline to 0×109/L (0%) (range 0–1 (0%–3%)) 
at month 4. There was no difference in median B cell counts 
between responders and non- responders. There were modest 
reductions in C reactive protein levels (median 2.65 mg/L 
(0–165) at baseline; 1.2 mg/L (0–183) at month 4) and erythro-
cyte sedimentation rate (21.5 mm/hour (1–149) to 12.5 mm/hour 
(2–100)) following treatment with glucocorticoids and ritux-
imab. Serum creatinine remained stable (92.5 µmol/L (37.1–472) 
at baseline and 97.3 µmol/L (42-542) at month 4). One hundred 
and thirty out of 188 (69.1%) patients tested positive for ANCA 
at baseline and 81/188 patients (43.1%) at month 4. There was a 
greater proportion of PR3- ANCA positive patients who became 
ANCA negative (53.2% to 33.1%) compared with MPO- ANCA 
patients (14.9% to 12.4%) (figure 3). The two individuals who 
switched from being ANCA negative at baseline to PR3- ANCA 
positive at month 4 entered remission.
safety
Forty- one SAEs occurred in 27 patients, including 13 severe 
infections (nine chest, three urinary and one gastrointestinal 
infection) in seven patients. Five out of 13 infections occurred 
within 4 weeks of the first induction dose of rituximab. In addi-
tion, there were 86 non- severe infections in 59 patients (online 
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Figure 3 Change in ANCA status between month 0 and month 4 only complete cases reported (n=158). Figures represent the number of individuals 
according to ANCA status. In addition to those displayed on the graph, two individuals were positive for MPO and PR3- ANCA at month 0. ANCA, 
antineutrophil cytoplasmic antibody.
Table 2 Adverse events according to glucocorticoid induction 
regimen
Total 1A 1b
Total number (%) of participants with an SAE 27 (14.3) 10 (18.5) 17 (12.7)
Total number (%) of participants with a 
serious infection
7 (3.7) 0 7 (5.2)
Total number (%) of participants with a non- 
serious infection
59 (31.4) 12 (22.2) 47 (35.1)
Number (%) of participants with IgG <5 g/L 51 (27.1) 27 (50.0) 24 (25.4)
1A: higher dose glucocorticoid induction regimen, starting at 1 mg/kg/day 
(maximum starting dose 60 mg/day); 1B: lower dose glucocorticoid induction 
regimen, starting at 0.5 mg/kg/day (maximum starting dose 30 mg/day).
SAE, serious adverse event.
supplementary table 2). Fifty- one patients had an IgG level less 
than 5 g/L at some point during the induction phase (table 2). 
Four patients (2.1%) died in the induction phase; causes of death 
included: pneumonia (2), cerebrovascular accident (1) and active 
vasculitis (1).
dIsCussIOn
These data from the induction phase of the RITAZAREM trial, 
the largest reported prospective cohort of patients with relapsing 
AAV, demonstrate that rituximab, in conjunction with gluco-
corticoids, is effective at reinducing remission in patients with 
AAV who have relapsed, regardless of previous therapy. A high 
proportion of patients (171/188, 90%) achieved remission by 
4 months, and it is notable that 71% of patients received the 
lower dose glucocorticoid regimen. Although there are retro-
spective series, the only previous prospective data on induction 
of remission for this subgroup of patients with ANCA- associated 
vasculitis was from the RAVE trial that observed a higher rate of 
remission in 50 relapsing patients treated with rituximab when 
compared with 50 relapsing patients treated with cyclophospha-
mide.7 11–15 Thus, these data confirm and extend the data on 
the efficacy of rituximab for relapsing GPA/MPA and supports a 
recommendation of rituximab for this indication.
The higher remission rate found in RITAZAREM versus RAVE 
may be due in part to the different definitions of remission. In 
RITAZAREM, remission was defined as a BVAS/WG ≤1 with a 
prednisolone dose ≤10 mg/day. The RAVE trial observed a lower 
remission rate of 64% at 6 months but required a BVAS/WG of 
zero and complete glucocorticoid withdrawal.7 The stricter defi-
nition of remission in RAVE, together with differences in trial 
design, and the enrolment in RAVE of a more severely affected 
patient population (median BVAS/WG 8.5 (5–13) for patients 
treated with rituximab), makes direct comparison between 
RITAZAREM and RAVE difficult. In the current study, only 
6 of the 17 patients who did not achieve remission (3.2% of 
the whole study population) clearly represented failure of the 
therapy. The remainder were withdrawn from the study protocol 
either due to investigator or participant decision (seven patients, 
3.7%) or died (four patients, 2.1%) within the induction phase. 
In this cohort, no baseline variables studied were predictive 
of failure of treatment response, although the small numbers 
of non- responders make it difficult for such an analysis to be 
definitive.
Induction regimens in AAV have been associated with high 
rates of SAEs, and these are more frequent and problematic 
than failures to control disease activity, thus improvements in 
the safety of induction regimens are required. In RITAZAREM, 
SAEs occurred in 14.3% of patients, which is a lower rate than 
seen in the RITUXVAS trial in which 42% of patients treated 
with rituximab experienced at least one SAE and the RAVE 
trial in which 22% of patients experienced at least one grade 3 
adverse event.6 7
In the treatment of AAV, concomitant use of glucocorticoids 
is a major contributor to SAEs, especially infective risks, and 
two glucocorticoid regimens were permitted in this study to suit 
physician preference. The choice of glucocorticoid regimen was 
not randomised, and thus may have been subject to bias, so the 
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relative efficacy of these two regimens cannot be completely 
analysed. Nonetheless, these two regimens appeared similarly 
effective with the lower dose approach providing approximately 
two- thirds of the total oral glucocorticoid exposure, and thus 
reduced dose glucocorticoids can be recommended as a treat-
ment option for this indication.
The key strength of the study lies in the number of patients 
recruited, making this the largest cohort of patients with relapsing 
AAV to be studied in a clinical trial, facilitating the collection 
of high- quality efficacy and safety data on a complex patient 
population. This is a typical population of patients relapsing 
with AAV, enriched for patients with PR3- ANCA positivity, 
with median prior disease duration of 5 years, prior exposure to 
cyclophosphamide and/or rituximab in the majority and a degree 
of established chronic damage, meaning that results are broadly 
applicable. A potential weakness of this study was the option 
for investigators to choose, rather than randomly assigning the 
glucocorticoid dosing regimen in a blinded manner. Prescribing 
practices for use of glucocorticoids in AAV vary, necessitating a 
pragmatic approach to trial design. However, investigators were 
required to select the dosing regimen at enrolment, and tapering 
schedules were standardised.
Achieving a negative serum ANCA test following induction 
therapy is associated with a lower subsequent risk of relapse in 
AAV.16 17 In the current study, despite 90% of patients achieving 
remission at month 4, 46% remained positive for serum ANCA 
at month 4, supporting data from the RAVE trial, in which 53% 
of patients treated with rituximab remained positive for ANCA 
at 6 months.7 Follow- up in the randomised phase of the RITAZ-
AREM trial will provide further insight into the significance of 
changes in ANCA levels.
These data from the first phase of RITAZAREM demonstrate 
that rituximab, in conjunction with even relatively low doses 
of glucocorticoids, is highly effective at reinducing remission 
in patients with AAV who have relapsed, with a safety profile 
similar to or better than previous studies.
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